Common Serious Side-Effect Of CAR T-Cell Therapy May Be Preventable – Forbes
Forbes |
Common Serious Side-Effect Of CAR T-Cell Therapy May Be Preventable
Forbes It has been a good month for CAR T-Cell therapies. On May 1st, the FDA handed out an approval to Novartis's controversially-priced Kymriah for treating adults with certain types of non-Hodgkin lymphoma. Today, simultaneous discoveries from scientists … |
